ProteinFind® Anti-CD63 Mouse Monoclonal Antibody
Catalog Number： HE904-01
Price：Please inquire first
Product Details
CD63, also known as platelet glycoprotein 40 (Pltgp40) or melanoma antigen 491 (ME491), is a widely expressed protein localized in the endosomal system and cell surface, and it is mainly found in late endosomes/multivesicles (MVBs) and lysosomes[1]. CD63 is associated with vesicle transport and the occurrence and metastasis of various tumors. In ovarian cancer, low expression of CD63 have been found to be associated with tumor metastasis[2]. In lung adenocarcinoma, low expression of CD63 is associated with tumor metastasis and poor prognosis[3]. And it also has been found that CD63 expression is negatively correlated with tumor invasion and metastasis in breast cancer and colon cancer[4, 5]. This product is the mouse anti-human CD63 monoclonal antibody,which is used for the specific detection of human CD63 by WB, IF and FC.
Storage
PBS (pH7.4), 0.05% ProClin 300, 50% Glycerol; at -20℃ for two years, avoid repeated freeze-thawing.
Shipping
Dry ice (-70℃)
[1] Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63 [J]. Exp Cell Res. 2009, 315(9): 1584-92.
[2] Zhijun X, Shulan Z, Zhuo Z. Expression and significance of the protein and mRNA of metastasis suppressor gene ME491/CD63 and integrin alpha5 in ovarian cancer tissues [J]. Eur J Gynaecol Oncol. 2007, 28(3): 179-83.
[3] Kwon MS, Shin SH, Yim SH, et al. CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung [J]. Lung Cancer. 2007, 57(1): 46-53.
[4] Sauer G, Kurzeder C, Grundmann R, et al. Expression of tetraspanin adaptor proteins below defined threshold values is associated with in vitro invasiveness of mammary carcinoma cells [J]. Oncol Rep. 2003, 10(2): 405-10.
[5] Sordat I, Decraene C, Silvestre T, et al. Complementary DNA arrays identify CD63 tetraspanin and alpha3 integrin chain as differentially expressed in low and high metastatic human colon carcinoma cells [J]. Lab Invest. 2002, 82(12): 1715-24.
